Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MK-1026 in hematologic malignancies
CTR20222899Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of suvorexant in hematopoietic malignancies, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), sponsored by Merck & Co.. Started Feb 2023; status: active.
02
Drugs
suvorexant
03
Conditions
hematopoietic malignancieschronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20222899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222899.